Prohibit online marketplaces from selling drugs in India: Traders body CAIT asks Govt

CAIT urged the government to impose a minimum penalty of Rs 1 lakh which may extend to Rs 10 lakh so that violators like Pharmeasy, Netmeds, Flipkart, Amazon Pharmacy, Tata1Mg etc. are suitably penalised.

Published On 2022-04-10 06:45 GMT | Update On 2022-04-10 06:46 GMT

New Delhi: Traders' body CAIT on Thursday asked the government to prohibit online marketplaces from selling drugs in the country, a day after e-retailer Flipkart announced its entry into the medicine vertical.

In a statement issued on Thursday, the Confederation of All India Traders (CAIT) said it has written to commerce minister Piyush Goyal and health minister Mansukh Mandaviya drawing their urgent attention to prohibit e-pharmacies from selling drugs in India so that the provisions of Drugs and Cosmetics Act and Rules (DC Act and Rules) are fully complied with.

CAIT's national president B C Bhartia and secretary general Praveen Khandelwal said that the DC Act and Rules regulates the import, manufacture, sale and distribution of drugs in the country, and has strict provisions in view of public health and safety.

On April 6, Walmart group firm Flipkart announced its foray into the healthcare segment by launching new app Flipkart Health Plus to leverage its reach and serve more than 20,000 pin code areas across the country.

Flipkart Health Plus platform plans to onboard over 500 independent sellers with a network of registered pharmacists for validation of medical prescriptions and accurate dispensation of medicines.

CAIT said that no person is permitted to import, manufacture, sell or distribute drugs without a valid licence or sell misbranded, adulterated or spurious drugs, or sell drugs without an original prescription.

Bhartia and Khandelwal also urged the government to ban e-pharmacies to prevent them from hiding behind intermediary provisions under Indian laws with an intention to avoid any liability, in case adulterated, spurious or counterfeit drugs reach the consumer.

The trade body called for a ban on marketplace intermediaries to put an end to deep discounting and predatory pricing, which hurts offline retailers.

CAIT also urged the government to impose a minimum penalty of Rs 1 lakh which may extend to Rs 10 lakh so that violators like Pharmeasy, Netmeds, Flipkart, Amazon Pharmacy, Tata1Mg etc. are suitably penalised.

"To prevent intermediaries from getting into creative agreements and operate marketplace e-pharmacy platforms, we have also requested the government to ensure that no person should be allowed to establish a web portal to act as an intermediary between the e-pharmacy entity and consumer," it said.

The industry body asked the government to ensure that drugs are disbursed only from a registered retail pharmacy and only by a registered pharmacist.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Prohibit online marketplaces from selling drugs in India: Traders body CAIT asks Govt

CAIT urged the government to impose a minimum penalty of Rs 1 lakh which may extend to Rs 10 lakh so that violators like Pharmeasy, Netmeds, Flipkart, Amazon Pharmacy, Tata1Mg etc. are suitably penalised.

Similar News

Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection Citing Safety Concerns

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

CDSCO Ends Emergency-Use Authorization of Baricitinib for COVID-19 Treatment

Merck gets USFDA priority review for 2 applications for Keytruda, Keytruda Qlex in combo with Padcev for bladder cancer

CDSCO Flags 112 Drug Batches Including Telmisartan, Pantoprazole, Cefixime, Glimepiride as Not of Standard Quality

Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis